USD10
KLRA Shares
About Kailera TherapeuticsKailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
USD10
KLRA Shares
About Kailera TherapeuticsKailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Stats
TRADING WINDOW
Closed
OPENS AT
Sep 1 at 1:30 PM GMT+0
MARKET CAP
$2B
OPEN PRICE
Not enough data
LOW (1Y)
$15.15
HIGH (1Y)
$28.23
LOW (24H)
$15.15
HIGH (24H)
$16.64
VOLUME (24H)
$798.47K
706,509.08%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $16.41 | |
1 Week | $16.78 | |
1 Month | $16.50 | |
1 Year | $26.00 |
Past performance is not a reliable indicator of future results.
Discover more
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.